Project Grant R21AI174903

Award Date 6/1/24
Completion Date 4/30/26
Dollars Obligated $1M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This $3,356,188 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to characterize the HIV-1 proviral reservoir in neonates and infants receiving very early antiretroviral therapy (ART) and combination ART with broadly neutralizing antibodies (bNAbs) towards achieving ART-free remission. The key objectives are to: (1) quantify and characterize the intact proviral pool, (2) evaluate HIV integration...
This federal Project Grant award, issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $681,278 to support research into the mechanisms driving the persistence of the HIV latent reservoir in people living with HIV on antiretroviral therapy. The key products or services to be delivered through this award include: 1) Fully characterizing the clonality distribution of intact and defective HIV...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,332,155 to Emory University to conduct research on developing virus and host-directed immunotherapies for curing HIV infection in an infant macaque model. The key objectives are to: Determine how activating the non-canonical NF-kB pathway with broadly neutralizing antibody (bNAb) administration during early...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,322 to support research into the mechanisms that create and sustain the HIV reservoir - a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at the Fred Hutchinson Cancer...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $794,045 to the Regents of the University of California, San Francisco (UCSF) to study host mechanisms that drive HIV reservoir decay and sustained viral control. The goal is to identify potential therapeutic candidates for HIV cure strategies. The award funds research to characterize the role of class II...
This $1,010,290 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at Emory University to investigate the role of alveolar macrophages as potential HIV reservoirs and drivers of residual inflammation and immune activation in people living with HIV (PLWH) on antiretroviral therapy. The study aims to: 1) Determine the contribution of alveolar macrophages as reservoirs...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $489,500 to The Children's Hospital of Philadelphia (CHOP) Research Institute to conduct research on the cellular identity of the intact HIV reservoir. The key objectives of this 2-year research project are to: 1) Investigate whether CD4+ T cells with provirus in closed chromatin are transcriptionally distinct from...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This $800,389 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this 5-year grant is to evaluate the safety and therapeutic potential of a novel treatment strategy for achieving sustained HIV remission. The proposed approach combines soluble IL-15/IL-15RA-FC with TGF-beta pathway blockade and therapeutic vaccination, to enhance anti-viral immunity and...

LONGITUDINAL ANALYSIS OF HIV RESERVOIR AND TYPE I/III INTERFERON SYSTEM IN PEOPLE WITH HIV WHO INITIATED ART DURING PRIMARY INFECTION - ABSTRACT EARLY INITIATION OF ANTIRETROVIRAL THERAPY (ART) DURING PRIMARY HIV INFECTION LEADS TO CLEAR PUBLIC HEALTH BENEFITS BY PREVENTING ONWARD HIV TRANSMISSIONS. HOWEVER, IT IS NOT CLEAR HOW THE TIMING OF EARLY ART INITIATION AFFECTS LONGER-TERM INDIVIDUAL OUTCOMES, SUCH AS CHRONIC IMMUNE ACTIVATION. CHRONIC IMMUNE ACTIVATION DURING HIV INFECTION LEADS TO IMMUNE DYSREGULATION AND EXHAUSTION THAT CONTRIBUTES TO DISEASE PROGRESSION AND OTHER CLINICAL PROBLEMS. HEIGHTENED IMMUNE ACTIVATION CONTINUES EVEN AFTER ART SUPPRESSES VIRAL LOADS BELOW THE LIMIT OF DETECTION. OUR GROUP PREVIOUSLY DEMONSTRATED THAT ONE PATHWAY INVOLVED IN IMMUNE ACTIVATION, EXPRESSION OF INTERFERON STIMULATED GENES (ISGS), IS PERSISTENTLY UPREGULATED DURING UNTREATED AND TREATED HIV INFECTION. BUILDING ON THOSE RESULTS, WE HYPOTHESIZE THAT (1) EFFECTIVE ANTIRETROVIRAL TREATMENT DOES NOT COMPLETELY REVERSE CHRONIC ISG ACTIVATION IN PEOPLE LIVING WITH HIV, (2) CHRONIC ACTIVATION OF THE IFN SYSTEM WILL BE LOWER IN PEOPLE WITH HIV (PWH) WHO STARTED ART EARLY, AND (3) HIGHER IFN SYSTEM ACTIVATION CORRELATES WITH A LARGER PROVIRAL RESERVOIR. IDENTIFYING ISG PATHWAYS THAT REMAIN ELEVATED FOLLOWING SEVERAL YEARS OF ART COULD IDENTIFY TARGETS FOR PREVENTING OR TREATING CO-OCCURRING INFLAMMATORY AND DEGENERATIVE DISEASES, WHICH ARE INCREASING IN PREVALENCE AS MORE AND MORE PWH HAVE REMAINED ON ART FOR DECADES. TO EVALUATE THESE HYPOTHESES, WE WILL USE A HIGHLY UNIQUE SET OF ARCHIVED SAMPLES, WITH LONGITUDINAL SAMPLES FROM INDIVIDUALS PRIOR TO HIV INFECTION, DURING PRIMARY INFECTION, AND AFTER TREATMENT INITIATION. THESE SAMPLES COME FROM A STUDY OF EARLY ART INITIATION IN WHICH 1) INDIVIDUALS WITHOUT HIV WERE FOLLOWED MONTHLY WITH SEROLOGY AND RNA TESTING TO DETECT HIV INFECTIONS SHORTLY AFTER ACQUISITION, AND 2) PARTICIPANTS DIAGNOSED WITH HIV WERE RANDOMIZED TO BEGIN ART IMMEDIATELY OR TO DEFER ART FOR 24 WEEKS. THEY WERE FOLLOWED WITH FREQUENT VISITS AND SAMPLE COLLECTIONS FOR UP TO 4 YEARS. IN THE PROPOSED STUDY, WE WILL MEASURE EXPRESSION OF ISGS IN 40 PARTICIPANTS (20 FROM EACH ART ARM) BEFORE HIV INFECTION, AFTER HIV DIAGNOSIS BUT BEFORE ART AND AT 6, 30 AND 48 MONTHS AFTER ART IS STARTED. USING THESE DATA, WE WILL DETERMINE WHETHER ISG EXPRESSION REMAINS ELEVATED AFTER 48 MONTHS OF ART RELATIVE TO PRE-INFECTION SAMPLES FROM THE SAME PARTICIPANT. SECOND, WE WILL EVALUATE IF REDUCTION OF ISG EXPRESSION FOLLOWING ART IS DIFFERENT AMONG THOSE IN THE IMMEDIATE VS. THE DEFERRED ART INITIATION ARMS. LASTLY, WE WILL ASSESS WHETHER ISG ACTIVATION CORRELATES WITH THE SIZE OF THE LATENT HIV RESERVOIR, AS HAS BEEN SUGGESTED BY ANIMAL MODELS BUT REMAINS UNKNOWN IN HUMANS.

Posted 5/31/24, 12:00 AM